Used in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. Its structure, a derivative of thalidomide-like compounds, enables selective binding to cereblon, facilitating the degradation of disease-related proteins. This makes it valuable in developing treatments for cancers such as multiple myeloma and other hematologic malignancies. Also explored in the design of PROTACs (proteolysis-targeting chimeras) for enhanced specificity and potency in drug development. Additionally, it exhibits potential immunomodulatory and anti-angiogenic properties similar to thalidomide, supporting research in anti-inflammatory applications for chronic diseases.